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Editor summary: 
A Novel Strategy  for Treating Colon Cancer 
In most patients, colon cancer arises from a mutation in the gene encoding APC, which results in 
constitutive activation of the β-catenin pathway. Inhibition of this pathway interferes with the continuous 
renewal of the epithelial cells that line the intestinal tract and therefore may confer only limited 
therapeutic benefit. Phesse et al. discovered that the signaling pathway involving the receptor gp130, the 
associated Jak kinases, and the transcription factor Stat3 enhanced the growth of intestinal tumors in 
mice. Conversely, genetic or pharmacological inhibition of this pathway reduced tumor growth by 
increasing the expression of genes encoding the p21 and p16 proteins that halt cell division, via a cell 
intrinsic mechanism. Thus, drugs targeting the Jak-Stat3 pathway, which are currently in clinical trials for 
the treatment of haematological malignancies, may also be useful for treating colon cancer.  
  
2 
 
 
Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-mediated 
intestinal tumour growth and regeneration  
 
 
Toby J. Phesse1,#, Michael Buchert1,#, Emma Stuart1, Dustin J. Flanagan2, Maree Faux1, Shoukat 
Afshar-Sterle1, Francesca Walker1, Hui-Hua Zhang1, Cameron J. Nowell1, Robert Jorissen1, Chin 
Wee Tan1, Yumiko Hirokawa1,  Moritz Eissmann1, Ashleigh R. Poh1, Jordane Malaterre3, Helen 
B. Pearson3, David G. Kirsch4, Paolo Provero5, Valeria Poli5, Robert G. Ramsay3, Oliver Sieber1, 
Antony Burgess1, Dennis Huszar6, Elizabeth Vincan2 and Matthias Ernst1,* 
 
 
 
1  Ludwig Institute for Cancer Research, Melbourne, Australia and The Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Australia and Department of Medical Biology, 
University of Melbourne, Australia 
2  Department of Anatomy and Cell Biology, University of Melbourne, VIC3052, and 
Victorian Infectious Diseases Reference Laboratories, North Melbourne, VIC3051 and 
School of Biomedical Sciences, Curtin University, Perth, WA6845, Australia. 
3  Peter MacCallum Cancer Centre, Melbourne, VIC3002, Australia and the Sir Peter 
MacCallum Department of Oncology, University of Melbourne, Parkville VIC3052, 
Australia. 
4  Departments of Radiation Oncology, Pharmacology and Cancer Biology, Duke University 
Medical Center, Durham, NC27710, USA. 
5  Department of Genetics, Biology and Biochemistry, University of Turin, 10126 Torino, 
Italy. 
3 
 
6 AstraZeneca, Oncology iMed, Waltham, MA 02451, USA. 
#  Authors contributed equally 
* Correspondence: matthias.ernst@wehi.edu.au  
4 
 
 
ABSTRACT 
 
Most colon cancers arise from somatic mutations in the tumor suppressor gene APC and these 
mutations cause constitutive activation of the Wnt to β-catenin pathway in the intestinal 
epithelium. Because Wnt-β-catenin signaling is required for homeostasis and regeneration of the 
adult intestinal epithelium, therapeutic targeting of the Wnt pathway is challenging. We found 
that genetic activation of the cytokine-stimulated pathway mediated by the receptor gp130, the 
associated Jak kinases, and the transcription factor Stat3, was required for intestinal regeneration 
in response to irradiation-induced damage in wild-type mice and for tumorigenesis in Apc-
mutant mice. Systemic pharmacological or partial genetic inhibition of gp130-Jak-Stat3 
signaling suppressed intestinal regeneration, the growth of tumors in Apc-mutant mice, and the 
growth of colon cancer xenografts. Mechanistically, the growth of Apc-mutant tumors depended 
on gp130-Jak-Stat3 signaling for induction of the polycomb repressor Bmi-1, and the associated 
repression of genes encoding the cell cycle inhibitors p16 and p21. However, suppression of 
gp130-Jak-Stat3 signaling did not affect Wnt-β-catenin signaling or homeostasis in the intestine. 
Thus, these data not only suggest a molecular mechanism for how the gp130-Jak-Stat3 pathway 
can promote cancer, but also provide a rationale for therapeutic inhibition of Jak in colon cancer. 
 
 
 
ONE SENTENCE SUMMARY 
Partial suppression of the gp130-Jak-Stat pathway inhibits intestinal tumor growth.  
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INTRODUCTION   
 
The lining of the mammalian intestine comprises a rapidly proliferating epithelial monolayer that 
undergoes continuous renewal (1). It provides two vital functions absorbing nutrients and water, 
and serving as a physical barrier that separates the immune system from luminal bacteria, 
antigens, and toxins.  Tissue homeostasis of the adult intestinal epithelium depends on cellular 
plasticity to enable self-renewal, proliferation and apoptosis, and to ensure effective wound 
healing without promoting malignant outgrowth. These processes are regulated in part through 
Wnt-β-catenin signaling (2, 3), which promotes proliferation of the epithelial stem cell 
compartment at the base of the intestinal crypt and is required for intestinal regeneration (4). Wnt 
ligands are secreted glycoproteins that activate the Frizzled family of G-protein coupled 
receptors and the co-receptors Lrp5 and Lrp6. Activation of Wnt receptor complexes leads to 
inhibition of a protein complex, which includes the tumor suppressor protein APC (adenomatous 
polyposis coli) and prevents ubiquitin-mediated degradation of the transcriptional co-activator β-
catenin (5). In greater than 80% of sporadic and familial colorectal cancers (CRC), mutations 
causing premature stop codons in APC induce constitutive accumulation and activation of β-
catenin in the nucleus and drive tumor formation (6, 7). 
 
Transcriptional regulation of many Wnt-β-catenin target genes, including the stem cell regulator 
Lgr5, is mediated through c-Myc (7). Systemic suppression of c-Myc in mice impairs 
homeostatic renewal of the intestinal epithelium (8), whereas ablation of c-Myc in intestinal 
epithelial cells (IECs) triggers repopulation from intestinal stem cells (3). Likewise, c-Myc is 
required for regeneration of intestinal crypts after γ-irradiation (4) and for intestinal hyperplasia 
in mice with conditional deletion of Apc in IECs (7). Therefore, therapies designed to interfere 
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with the Wnt-β-catenin pathway in CRC are likely to impact on homeostasis of the intestine, 
leading to dose-limiting toxicities and possibly limited clinical utility.  
 
The gp130-Jak-Stat signaling pathway contributes to intestinal homeostasis, wound healing 
response and cancer (9).  Binding to cytokines, including interleukin (IL) 6 or IL11, via their 
ligand specific receptor α-subunits causes homodimerization of the transmembrane receptor β-
subunit gp130 and activation of Janus kinases (Jak1, Jak2, or Tyk2), which are constitutively 
associated with gp130. Jaks phosphorylate tyrosines in gp130 that then provide docking sites for 
the latent transcription factor Stat3, and also to some extent for Stat1. Subsequent tyrosine-
phosphorylation of Stat3 by Jaks results in dimerization, nuclear translocation, and activation of 
Stat3-target genes, including Socs3 and Ccnd1 (10).  IL11-dependent engagement of gp130-Jak-
Stat3 pathway enables the intestine to respond to inflammatory stimuli that result from disruption 
of the protective epithelial monolayer (11). Accordingly, impairment of gp130-specific Stat3 
activation in gp130ΔStat/ΔStat mice, in which the Stat3-binding region in gp130 is deleted, increases 
susceptibility to experimentally induced colitis (12). Conversely, activation of Stat3 confers 
resistance to colitis in gp130F/F mice, which contain a homozygous mutation that results in a 
Y757F amino acid substitution in gp130 that prevents binding of Socs3, a negative regulator of 
gp130-Jak-Stat3 signaling (12). Furthermore, excessive activation of Stat3 promotes colitis-
associated colon cancer (13). Phosphorylation of Stat3 also occurs during the adenoma-to-
carcinoma transition of in human colorectal cancer (14) and localizes to the invasive fronts of 
CRC tumors (11). 
 
7 
 
Here, we investigated the functional interaction between gp130-Jak-Stat and Wnt-β-catenin 
signaling pathways in CRC. We found that partial inhibition of the gp130-Jak-Stat3 pathway did 
not affect normal intestinal homeostasis but impaired regeneration of the intestinal epithelium in 
response to irradiation and slowed down the growth of tumors in Apc-mutant mice and mice with 
xenografts of human APC-mutant CRC cells. Manipulation of gp130-Jak-Stat3 signaling did not 
affect the expression of Wnt target genes in tumors, but increased the expression of the gene 
encoding the polycomb repressor Bmi-1. Similar to inhibition of gp130-Jak-Stat3 signaling, 
heterozygous knockout of Bmi-1 in Apc-mutant mice reduced tumor growth and increased the 
abundance of the cell cycle inhibitors p16 (also known as Ink4a and encoded by Cdkn2a) and 
p21 (also known as Waf1 or Cip1 and encoded by Cdkn1a). Thus, the gp130-Jak-Stat3 pathway 
may serve as a “rheostat” to fine-tune the proliferative response of the intestinal epithelium 
during excessive activation of the Wnt-β-catenin pathway and therefore, may be amenable as a 
therapeutic target for APC-mutant CRC. 
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RESULTS 
gp130-Jak-Stat3 signaling is required for intestinal regeneration in response to irradiation 
We asked whether regeneration of the intestinal epithelium in response to radiation-induced 
damage required gp130-Jak-Stat3 signaling. We used immunohistochemistry for proliferating 
cell nuclear antigen (PCNA) to visualize proliferating IECs in regenerating intestinal crypts of 
mice 72 hours after 14Gy of whole body γ-irradiation (4). We examined mice with a 
heterozygous deletion that eliminates the Stat3-binding region of gp130 (gp130ΔStat/+ mice) (12) 
or heterozygous deletion of Stat3 (Stat3+/-) (15). We found significantly fewer regenerating 
crypts in irradiated gp130ΔStat/+ or Stat3+/- mice compared to irradiated wild-type mice (Fig. 1A).  
We also asked whether pharmacological inhibition of Jak-Stat signaling could affect 
regeneration buy using AZD1480, an ATP-competitive kinase inhibitor with specificity for Jak1 
and Jak2 (16). We found that irradiated wild-type mice, which were gavaged daily with 
AZD1480 for the 3 days prior to irradiation and during the 72h follow-up period, displayed 
reduced epithelial regeneration compared to vehicle-treated, irradiated wild-type mice (Fig. 1A).    
 
Wnt-β-catenin signaling is required for the regeneration of IECs after irradiation (4); thus, we 
examined whether Stat3 signaling was required for Wnt signaling in this context.  Consistent 
with the presence of active Wnt-β-catenin signaling (4), we found that c-Myc and β-catenin 
accumulated in the nuclei of cells at the base of regenerating crypts in irradiated wild-type mice 
(Fig. 1B). We also detected nuclear c-Myc and β-catenin in cells of the stunted, nonregenerating 
crypts of irradiated gp130ΔStat/+ mice (Fig. 1B). Likewise, expression of the β-catenin target 
genes Lgr5, Fzd7, Axin2, Ccnd2, Cd44, and c-Myc (17) was comparable between IECs of 
irradiated wild-type and gp130ΔStat/+ mice (Fig. 1C).  In contrast, irradiation-induced expression 
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of Ccnd1, which encodes the cell cycle regulatory protein cyclin D1 and is a target of both Wnt-
β-catenin and gp130-Jak-Stat3 signaling, was reduced in irradiated gp130ΔStat/+ mice compared to 
irradiated wild-type mice (Fig. 1C).   
 
To assess whether Stat3 signaling was required in IECs for crypt formation, we analyzed the 
formation of organoids in three dimensional cell cultures established from isolated crypts of the 
small intestine and the colon (18). Organoids established from wild-type mice, and grown in 
media with the Stat3 inhibitor S3I-201 (19) or the Jak inhibitor AZD1480 had fewer crypt-like 
outgrowths than those grown in vehicle-containing medium (Figs. 1D and S1A and B).  In 
contrast, organoids established from gp130F/F mice, or those from wild-type mice grown in 
media containing IL11, had more crypt-like outgrowths than organoids established from wild-
type mice and grown in control media (Figs. 1D and S1A and B).  Thus, gp130-dependent Stat3 
signaling facilitates regeneration of IECs in parallel to Wnt-β-catenin signaling, and this is likely 
to occur by an IEC-autonomous mechanism.   
 
gp130-Jak-Stat3 signaling is required for intestinal tumorigenesis caused by loss of Apc  
Stat3 promotes colitis-associated colon cancer (13). We investigated whether gp130-Jak-Stat3 
signaling was also required for intestinal tumorigenesis in the absence of overt colitis. We used 
mice heterozygous for the ApcMin allele (ApcMin/+ mice), which encodes a non-functional Apc 
protein similar to that found in human familial adenomatous polyposis. ApcMin/+ mice undergo 
spontaneous somatic loss of the wild-type allele of Apc resulting in constitutive activation of β-
catenin that leads to the formation of multiple tumors in the small intestine and colon (20). We 
found that genetic reduction of gp130-dependent Stat3 activation reduced the number and size of 
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tumors in the small and large intestines of ApcMin/+; gp130ΔStat/+ mice compared to ApcMin/+ mice 
at 150 days of age (Fig. 2A).  The few, small tumors that arose in ApcMin/+; gp130ΔStat/+ mice by 
150 days of age were tubular adenomas (Fig. S1C) and did not progress to the invasive 
adenocarcinomas reported for mice with complete lack of Stat3 expression in IECs (21). 
 
We also analyzed whether gp130-Jak-Stat3 signaling affected early stages of tumor formation by 
staining the colon of 100 day old ApcMin/+ mice with methylene blue (22).  ApcMin/+; Stat3+/- mice 
had fewer methylene blue-positive foci than ApcMin/+ mice (Fig. 2B and C). To assess whether 
activation of gp130-Jak-Stat3 signaling affected tumorigenesis in ApcMin/+ mice, we used mice 
homozygous for the gp130 mutation that results in the Y757F substitution in gp130 and prevents 
its negative regulation by Socs3 (gp130F/F mice) (12). We found that the colons of ApcMin/+; 
gp130F/F mice had more and larger methylene blue-positive foci than ApcMin/+ mice at 100 days 
of age (Fig. 2B and C). We confirmed that genetic manipulation of gp130-Jak-Stat3 signaling 
affected expression of the Stat3 target gene Socs3 but the expression of the Wnt-β-catenin target 
gene c-Myc was comparable in intestinal tumors of ApcMin/+; gp130F/F, ApcMin/+; Stat3+/- , and 
ApcMin/+ mice (Fig. S1D).  We also assessed whether the increased tumor burden in ApcMin/+; 
gp130F/F mice was a consequence of impaired MAPK signaling, which occurs in cells of 
gp130F/F mice as a consequence of the Y757F substitution mutation and prevents engagement of 
the Shp2-Erk signaling cascade (12). However, the phosphorylation of Thr202/Tyr204 of p42/44 
MAPK was comparable in intestinal tumors of ApcMin/+; gp130F/F and ApcMin/+ mice (Fig. S1E). 
Thus, gp130-Jak-Stat signaling rather than gp130-dependent MAPK signaling was required for 
intestinal tumor initiation and growth in ApcMin/+ mice. 
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gp130-Jak-Stat3 signaling affects tumor burden in ApcMin mice independent of loss of Apc 
heterozygosity 
Sustained activation of Stat3 can enable cells to overcome the DNA replication checkpoint 
response (23), leaving open the possibility that aberrant chromosome segregation in cells with 
altered gp130-Jak-Stat3 signaling could modify the kinetics of loss of heterozygosity of Apc in 
ApcMin/+ mice. Therefore, we assessed the role of gp130-Jak-Stat3 signaling in tumorigenesis in 
mice with simultaneous inactivation of both alleles of Apc in intestinal stem cells. We expressed 
tamoxifen-inducible Cre-recombinase under the control of the intestinal stem cell marker Lgr5 in 
mice with homozygous floxed alleles of Apc (Lgr5CreERT2; Apcfl/fl mice) (24). We found that 35 
days after tamoxifen injection, adult Lgr5CreERT2; Apcfl/fl mice had tumors widespread throughout 
the small intestine and colon (Fig. 3A and fig. S2A). In contrast, tumours in both the small 
intestine and colon were significantly smaller when gp130-Jak-Stat3 signaling was reduced in 
Lgr5CreERT2; Apcfl/fl; gp130ΔStat/+ mice (Fig. 3A and fig. S2A).    
 
IEC-specific gp130-Jak-Stat3 signaling is required for the growth of Apc mutant intestinal 
tumors  
In mice, immune cell-specific gp130-Jak-Stat3 signaling can enable anti-tumor immunity (25), 
while IEC-specific Stat3 facilitates colitis-associated colon cancer (13). To assess whether Stat3 
was required cell autonomously in IECs for tumor growth, we selectively inhibited Stat3 
expression in IECs using Lgr5CreERT2 and a heterozygous floxed allele of Stat3. The small 
intestines and colons of Lgr5CreERT2; Apcfl/fl; Stat3fl/+ mice were almost free of adenomas (Fig. 3A 
and S2A), and the few tumors that developed were tubular adenomas similar to those found in 
ApcMin/+; gp130ΔStat/+ mice (Fig. S1C). This is in stark contrast to the invasive behaviour of 
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tumors in ApcMin/+ mice comprised of IECs with conditional homozygous deletion of Stat3 (21). 
The latter had been attributed to compensatory increase in Stat1 abundance, which we also 
observed in tumors of Lgr5CreERT2; Apcfl/fl; Stat3fl/fl mice, when compared to tumors of 
Lgr5CreERT2; Apcfl/fl; Stat3fl/+ or of Lgr5CreERT2; Apcfl/fl mice (Fig. S4B).  Collectively, this data 
suggests that partial inhibition of the gp130-Jak-Stat3 pathway impaired intestinal tumorigenesis 
through an epithelial cell intrinsic mechanism without changing the cellular behavior of the 
tumor cells. 
 
Inhibition of gp130-Jak-Stat3 signaling does not affect the accumulation of β-catenin in 
Apc-mutant tumors 
To explore the functional consequences of simultaneous activation of β-catenin and reduction of 
gp130-Jak-Stat3 signaling, we assessed the colocalization of nuclear β-catenin and PCNA (24) 
by immunohistochemistry. All tumors in Lgr5CreERT2; Apcfl/fl mice, and the few small emerging 
tumors in Lgr5CreERT2;Apcfl/fl; gp130ΔStat/+ mice, labelled robustly for nuclear β-catenin  (Fig. 3B) 
suggesting that high Wnt-β-catenin signaling persisted despite impaired gp130-Jak-Stat signaling. 
However, tumors in Lgr5CreERT2; Apcfl/fl; gp130ΔStat/+ mice had significantly fewer cells that were 
positive for both nuclear β-catenin and PCNA than those from Lgr5CreERT2; Apcfl/fl mice (Fig. 3B), 
indicating that high Wnt-β-catenin signaling was not sufficient to effectively promote cell 
proliferation in tumors with partially impaired gp130-Jak-Stat3 signaling.  
 
 
Pharmacological inhibition of gp130-Jak-Stat3 signaling inhibits tumor initiation and 
growth 
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Various small molecules that target the catalytic activity of Jak are in clinical development as 
therapies for haematological malignancies (26). Therefore, we explored whether 
pharmacological inhibition of Jak kinases could replicate the benefit conferred by genetic 
reduction of gp130-Jak-Stat3 signaling. Oral daily gavage of AZD1480 reduced tumor burden in 
Lgr5CreERT2; Apcfl/fl mice when assessed 35 days after administration of tamoxifen (Figs. 4A and 
S2A). Furthermore, in ApcMin/+ mice, administration of AZD1480 from 6 to 12 weeks of age 
reduced the number of tumors and decreased tumor size compared to those from mice treated 
with vehicle alone (Fig. 4B), suggesting that Jak inhibition prevented the formation of new 
tumors and blocked the growth of existing ones. These data suggest that pharmacological 
inhibition of Jak may be relevant for the treatment of human CRC. 
 
Inhibition of the gp130-Jak-Stat3 pathway causes growth arrest in human CRC cells with 
mutation in the Apc-β-catenin pathway 
We asked if co-activation of Stat3 and β-catenin occurs in human CRC and is required for the 
growth of established human CRC tumors. We evaluated gene expression in two independent 
cDNA microarray data sets from CRC patients (27, 28). We observed a marked increase of target 
genes for the Wnt-β-catenin (17, 29) and Stat3 signaling pathways (30, 31) in human CRC 
samples when compared to matched normal colons (Fig. S3).  
 
In order to assess whether inhibition of Jak activity conferred therapeutic benefits to advanced-
stage human CRC xenografts in mice, we administered AZD1480 to immune-compromised mice 
(BALB/c-nude) carrying CRC cell line xenografts of SW480 (mutant for APC, KRAS, TP53), 
DLD1 (mutant for APC, TP53, PIK3CA), LIM1899 (mutant for CTNNB1 encoding β-catenin, 
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KRAS), or RKO (mutant for PIK3CA, BRAF) cells. AZD1480 inhibited the growth of xenografts 
from all cell lines with mutations in the Apc-β-catenin pathway, but not from RKO cells (Fig. 5A 
and S4A). Complete ablation of Stat3 in mouse embryo fibroblasts can induce a compensatory 
increase in Stat1, thereby skewing the IL6 response towards a Stat1-interferon-γ-dependent 
pathway and associated anti-tumour immune response (32). However, the abundance of Stat1 
(Fig S4B) and the expression of the prototypic interferon-γ-Stat1 pathway target gene IP-10 (32) 
were unaffected in SW480 xenografts of AZD1480-treated mice when compared to vehicle-
treated mice (Fig. S4C). Since the BALB/c-nude host mice are also immune compromised, these 
results collectively support the notion that inhibition of gp130-Jak-Stat3 signaling limits tumor 
growth through mechanisms independent of restoring the adaptive anti-tumor immune response 
(25).  
 
The observation that AZD1480 did not inhibit the growth of RKO xenografts suggested that the 
gp130-Jak-Stat3 pathway may be rate limiting only in CRC cells with mutations that confer 
constitutive activation of β-catenin. To directly test this hypothesis, we used an isogenic pair of 
CRC cell lines comprising parental SW480 cells, which express only mutated APC, and 
SW480APC cells, which are engineered to re-express wild-type APC (33). Compared to parental 
SW480 cells, SW480APC cells had reduced abundance of total and nuclear β-catenin and 
consequently reduced ability to activate a Wnt reporter (TOPFLASH) (Fig. S5A and B). When 
exposed to IL11, a gp130-activating cytokine that plays a major role in the gastrointestinal 
epithelium (11), SW480 and SW480APC cells showed a similar increase in Tyr705 phosphorylated 
Stat3, which was abrogated by simultaneous exposure to AZD1480 (Figs. S5C and D). However, 
exposing SW480 or SW480APC cells to AZD1480 or IL11 did not alter the abundance or 
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localization of β-catenin or the activity of TOPFLASH (Fig. S5A, C and E). Meanwhile addition 
of AZD1480 or S3I-201 impaired colony formation in soft agar of SW480, but not of SW480APC 
cells (Figs. 5B), despite reducing the expression of SOCS3 in both cell lines (Fig. S5F). Exposure 
to IL11 increased colony formation of both SW480 and SW480APC cells (Fig. 5B), suggesting 
that gp130-Jak-Stat3 signaling can stimulate IEC proliferation irrespective of APC mutational 
status. Exposing SW480 or SW480APC cells to an inhibitor of the epidermal growth factor 
receptor, which is frequently overexpressed in CRC (34) and may mediate Stat3 activation 
during epithelial regeneration of the midgut in flies (35), did not affect colony formation (Fig. 5B) 
or SOCS3 expression (Fig. S5F). Thus, Jak-mediated activation of Stat3 was rate-limiting for the 
proliferative response of SW480 cells with constitutive activation of β-catenin, suggesting a 
specific role of gp130-Jak-Stat3 signaling in tumor cells with aberrant β-catenin signaling. 
   
Inhibition of gp130-Jak-Stat3 signaling does not affect intestinal homeostasis 
We observed that gp130-Jak-Stat3 signaling regulated intestinal regeneration without altering 
expression of Wnt-β-catenin target genes (Fig. 1B and C). To investigate whether inhibition of 
gp130-Jak-Stat signaling impaired tumor formation also without affecting the high aberrant Wnt-
β-catenin signaling observed in Apc-mutant CRC xenografts, we monitored gene expression. As 
expected, we observed that SW480 tumors from AZD1480-treated mice had reduced expression 
of the STAT3 target genes SOCS3 and CCND1, but not of the Wnt-β-catenin target genes MYC 
and LGR5 compared to vehicle-treated mice (Fig. 6A). Likewise, immunohistochemical analysis 
revealed similar amounts of β-catenin and the protein encoded by the Wnt-β-catenin target gene 
CD44 in SW480 xenografts from AZD1480-treated and vehicle-treated mice (Fig. S7B).  
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Stat3 is essential for survival of intestinal stem cells (36), and therefore, inhibition of gp130-Jak-
Stat3 signaling could affect normal intestinal homeostasis. We analysed non-cancerous regions 
of the small intestines and colons of BALB/c-nude mice carrying  SW480 xenografts, which 
were injected with 5-bromo-2'-deoxyuridine (BrdU) and gavaged daily with AZD1480 or vehicle 
control for 14 days.  In addition, we labelled sections of these intestines with the periodic acid-
Schiff (PAS) method to detect mucins (37) and with antibodies to detect lysozyme, a marker of 
Paneth cells (38). This analysis revealed a comparable size of the proliferative and differentiated 
IEC compartments in the small intestines of AZD1480- and vehicle-treated mice (Fig. S6A). 
Moreover, the positioning of Paneth cells, which is disrupted by excessive Wnt-β-catenin 
signaling (17), was similar in AZD1480- and vehicle-treated mice (Fig. S6A). Consistent with 
this observation, the expression of Wnt-β-catenin target genes was similar in IECs isolated from 
AZD1480- and vehicle-treated mice (Fig. S6B). Disruption of intestinal homeostasis can lead to 
loss of body weight; however, up to two weeks of AZD1480 administration did not affect total 
body weight in these mice (Fig. S6C). Thus, partial systemic inhibition of gp130-Jak-Stat3 
signaling had no overt effects on intestinal homeostasis, and is likely to be well tolerated.  
 
gp130-Jak-Stat3 signaling suppresses cell cycle inhibition by p16 and p21 upregulation via 
the corepressor Bmi-1 
We hypothesized that inhibition gp130-Jak-Stat3 activation may induce growth arrest in Apc-
mutant cells. Intestinal tumors of Lgr5CreERT2; Apcfl/fl; gp130ΔStat/+ mice had increased abundance 
of the cell cycle inhibitor p21 compared to tumors in Lgr5CreERT2; Apcfl/fl mice (Fig. S7A). 
Likewise, tumors in ApcMin/+; gp130ΔStat/+ mice had increased abundance of p16 (Fig. 6B) and 
p21 (Fig. 6C) compared to tumors in ApcMin/+ littermates. Similarly, SW480 xenografts from 
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AZD1480-treated mice had increased abundance of p21 (Fig. 6D) and expression of CDKN1A, 
the mRNA encoding p21 (Fig. 6A) than tumors in vehicle-treated mice.  
Because the polycomb-group protein Bmi-1 transcriptionally represses Cdkn1a and Cdkn2a, 
which encodes p16 (39), we investigated whether gp130-Jak-Stat3 signaling affects the amount 
of Bmi-1. Expression of Bmi1 was increased in IECs isolated from gp130F/F mice compared to 
those from wild-type mice (Fig. S7C). Injection of IL11 also increased the expression of Socs3 
and Bmi1 in IECs isolated from gp130F/F mice (Fig. S7D). In contrast, the Bmi-1 mRNA (Fig. 
6A) and protein (Fig. S7B) were reduced in SW480 xenografts from AZD1480-treated mice 
compared to vehicle-treated mice.  
 
We analyzed whether Bmi-1 was a direct target of Stat3. Sequence analysis of Bmi1 identified a 
putative Stat3-binding site in intron 1 starting at nucleotide position 4077 (Fig. S7E), and which 
was similar to the Stat3 consensus binding motif CTCNNNGAG (40). Moreover, exposing 
SW480 cells to IL11 increased chromatin immunoprecipitation (ChIP) of a region of intron 1 of 
BMI1 using an antibody for Stat3 (Fig. 6E). We created a luciferase reporter construct containing 
a region (base pairs 18681328-18681883; chr 2 of intron 1 of Bmi1. Exposing human embryonic 
kidney (HEK)293T cells to Hyper-IL6, a designer fusion protein comprising IL6 and the soluble 
part of the IL6Rα (41)  significantly increased the activity of this reporter (Fig. S7F) to a similar 
degree as other reporters with single intronic Stat3-binding sites (42). Thus, these data support 
the conclusion that Stat3 directly binds to Bmi1 and induces its transcription in a gp130-Jak-Stat3 
signaling-dependent manner. 
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We directly tested whether Bmi1was required for intestinal tumor growth in mice. Heterozygous 
knockout of Bmi-1 (Bmi1+/-) decreased the size of tumors (Fig. 6F) and increased the abundance 
of p21 and p16 in tumors (Figs. 6B and C) in the small intestine when crossed on to a ApcMin/+ 
mutant background. Collectively, these data suggest that gp130-Jak-Stat3 signaling is rate-
limiting for the growth of Apc-mutant intestinal tumors by repressing expression of the cell cycle 
inhibitors p21 and p16 through induction of the transcription of Bmi1 (Figure summary).  
19 
 
DISCUSSION 
 
Wnt-β-catenin signaling is required for the homeostasis and regeneration of the intestinal 
epithelium (4, 5) and is an etiological factor for the progression of intestinal tumors (43). Here, 
we found that inhibition of the gp130-Jak-Stat3 pathway limits the proliferative response of IECs 
during intestinal regeneration and tumorigenesis. 
 
Excess activation of Stat3 in IECs due to the release of inflammatory cytokines by infiltrating 
myeloid cells suppresses apoptosis and promotes proliferation in mouse models of colitis-
associated CRC (13). Here, we found that genetic activation of the gp130-Jak-Stat3 pathway 
promotes the formation of intestinal tumors in the absence of overt inflammation and is required 
for regeneration of intestinal epithelia in response to γ-irradiation. Systemic reduction of Stat3 
expression or suppression of gp130-mediated activation of Stat3 reduced the number and size of 
tumors and impaired regeneration in the intestine. Likewise, IEC-specific reduction of Stat3 
expression also reduced tumorigenesis that resulted from Apc gene inactivation. Furthermore, the 
growth of xenografts of human APC-mutant CRC cell lines in immune-compromised mice was 
impaired by systemic administration of AZD1480. Human CRC cells, irrespective of their APC 
status, had basal STAT3 activity, which was modulated in response to inhibition or IL11-
mediated stimulation of gp130-Jak activity. Furthermore, our data using epithelial organoid 
cultures suggest that at least a subset of IECs have paracrine or autocrine feed-forward 
mechanisms to produce and respond to one or more gp130-activating cytokines (11). Thus, our 
results suggest that the anti-tumor effect of Stat3 suppression was mediated by IEC-intrinsic 
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mechanisms and not the adaptive immune response, which can be reactivated in myeloid, 
dendritic, and natural killer cells in mice with systemic inhibition Stat3 (44).  
 
Because the gp130-Jak-Stat3 and Wnt-β-catenin pathways promote the expression of common 
target genes, including MYC and CCND1 (45, 46), it is possible that these pathways cooperate in 
tumor cells to induce transcription of these genes above a threshold required for cell proliferation. 
However, genetic or pharmacological inhibition of Stat3 did not reduce the accumulation of 
nuclear β-catenin or the expression of β-catenin target genes (7).  
 
Our data suggested that Bmi-1 plays a role in controlling cell proliferation in intestinal cells with 
increased activation of β-catenin. Bmi1 is overexpressed in various solid cancers (47, 48), 
including CRC (49), where increased Bmi1 expression correlates with poor prognosis (50).  Bmi-
1 is a regulatory subunit of the polycomb repressor complex-1. In embryonic fibroblasts cells, 
BMI-1 represses transcription of CDKN2A, which encodes the cell cycle inhibitory proteins p16 
and p14Arf (39). In mouse neural stem cells, Bmi-1 also represses expression of Cdkn1A, 
encoding the cell cycle inhibitor p21 (51).  Knockdown of Bmi-1 causes cell cycle exit of 
cultured CRC cells with high Wnt-β-catenin signalling, but does not reduce the expression of 
Wnt-β-catenin target genes in these cells (52).  Likewise, activation of β-catenin in Bmi1 
haploinsufficient mice only results in small intestinal adenomas (53).  The latter observation is 
functionally compatible with a role of Bmi-1 in self-renewal of Lgr5+ intestinal stem cells 
(reviewed in (54). 	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Linking the proliferative capacity of intestinal crypts to a “gp130/Stat3 rheostat” appears 
phylogenetically conserved, as it is also required for regeneration of the fly mid-gut (35).  In 
mammals, this enables the intestine to confine rapid mucosal regeneration to sites of greatest 
damage and hence greatest inflammation (55).  This mechanism is reinforced by the capacity of 
the inflamed stroma to convert IEC through a NF-κB dependent mechanism to intestinal stem 
cells (56). Accordingly, homozygous gp130ΔStat mice display prolonged wounding of the 
intestinal mucosa and associated ulceration (57).  Conversely, when the regenerative process is 
hijacked by APC- or β-catenin mutant cells, and irrespective of additional compounding 
mutations (e.g. KRAS, TP53), excessive STAT3 activity fuels the growth of the corresponding 
tumors. Accordingly, excessive STAT3 signaling is observed in a majority of human CRC (58). 
Here we provide comprehensive evidence that partial suppression of systemic gp130-Jak-Stat3 
signaling is sufficient to limit tumor growth by reducing Bmi-1 dependent repression of p21 and 
p16 in models of familial inherited and sporadic CRC (Fig. 6G). Consistent with this model, 
intestinal tumorigenesis in fully gp130-Jak-Stat3 signaling-proficient Apc-mutant mice remains 
unaffected after ablation of p21 (59), because here we showed that in these situations p21 
expression is already repressed through a Bmi-1-dependent mechanism.  	  
 
A major obstacle to targeting Wnt-β-catenin signaling in cancer is the reliance of the intestinal 
epithelium on this pathway for renewal and regeneration. Tankyrase inhibitors, which promote 
degradation of β-catenin, have limited clinical utility for cancer because of toxicity associated 
with inhibition of IEC homeostasis (60). Other recent strategies have focused on mTorc1 (61), 
Notch (62), and components of other pathways that are not mutated in CRC but are rate-limiting 
for CRC proliferation. Clinical trials with gamma-secretase inhibitors, which block Notch 
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signaling, reveal gastrointestinal toxicity (63), whereas single agent therapies targeting the 
mTOR pathway conferred limited benefit (64). Here, we found that partial inhibition of gp130-
Jak-Stat3 signaling selectively blocked proliferation of intestinal tumors driven by APC-
mutations without perturbing intestinal homeostasis or causing the side-effects common in 
models using complete Stat3 ablation (36, 65). Therefore, our findings in mice provide proof of 
concept for the development of existing gp130-Jak-Stat3 pathway inhibitors as therapeutic 
modalities for CRC. 
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MATERIAL AND METHODS 
 
Mice 
All procedures involving animals were approved by the Ludwig Institute for Cancer Research 
Department of Surgery Animal Ethics Committee and the Walter and Eliza Hall Institute Animal 
Ethics Committee. The gp130F/F, gp130ΔStat/+, Stat3+/-, ApcMin/+ and Lgr5CreERT2; Apcfl/fl mice have 
been descried previously (12, 15, 57) and compound ApcMin/+; gp130F/F, Lgr5CreERT2; Apcfl/fl; 
gp130ΔStat/+ and ApcMin/+; gp130ΔStat/+ strains were derived from corresponding inter-crossings. 
Lgr5CreERT2; Apcfl/fl; Stat3fl/+ and ApcMin/+; Bmi1+/- mice were generated from Stat3fl/fl (66) and 
Bmi1+/- mice (67), respectively. All mice were co-housed and unless indicated, all mice were on 
an inbred C57BL/6 genetic background using appropriate littermates as controls. A single daily 
Tamoxifen injection occurred over 4 consecutive days with 3mg/mouse on day 1 and 2mg/mouse 
during the following days. 
 
Irradiation induced regeneration 
Adult mice were irradiated with a single dose of 14 Gy of γ-irradiation (0.414 Gy/min) and 
intestines were collected 72 hours later (4).  
 
Tumor xenografts  
Female BALB/c-nude mice were injected subcutaneously with 2x106 SW480 cells, or 5x106 
DLD1, LIM1899 (51) and RKO cells. Cells were resuspended in Matrigel (BD Biosciences)/ 
PBS (1:1) to a final volume of 200 µl.  Once tumors became palpable (>100 mm3) approximately 
5 days later, AZD1480 (30 mg/kg, Astra-Zeneca) was administered by daily oral gavage (16). 
BrdU was injected i.p. at 50mg/kg, 2h prior to tissue collection. 
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Histology 
Mouse tissue collection and processing was carried out as previously detailed (4). Hematoxilin 
and Eosin-stained sections were scanned using an Aperio ScanScope XT (Aperio, USA) 
pathology slide scanner with a 20x PlanApo NA 0.6 objective and areas of interest were 
extracted using Aperio ImageScope software v11.1.2.760. Periodic Acid/Schiff stain was 
performed as described (7). Tumor burden was estimated by measuring the area covered by 
adenomas on histological cross-sections of rolled intestines using MetaMorph software v7.7.7, 
and then normalized to the length of the intestinal section on that slide (24). 
 
Organoid Culture 
Intestinal crypts from small intestines were harvested, washed and resuspended at 2000 crypts 
per ml of Matrigel (BD Biosciences) and 50 µl was then dispensed in each well of a 24-well 
plate. Once the Matrigel had set, serum-free culture medium was added, and the organoids were 
cultured for seven days as described (18). Organoid cultures were imaged on a Nikon Ti-E 
microscope using DIC contrast with a 10x PlanApo NA 0.3 objective. A focal stack of images 
was collected 10 µm apart and processed through the “Best Focus” function of MetaMorph 
v7.7.7 (Molecular Devices, USA) to generate the final image of individual organoids.   
 
Tissue Culture and Soft Agar Colony Growth Assay 
SW480 and SW480APC cells (33) were seeded in 2 ml of RPMI media supplemented with 10 % 
FBS and 1 % penicillin/streptomycin in 35 mm culture dishes at a density of 2x105 cells per dish.  
Three days later cultures were exposed to AZD1480 (2 µM) for 30 min. Co-immunofluorescence 
was then performed with antibodies to rabbit phospho-Stat3 (Tyr705, Santa Cruz #9134s, 1:200 
dilution) and mouse β-catenin (Transduction Laboratories, 1:400).  
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Colony formation assays of SW480 cells in soft agar were performed as described (33) in the 
presence of methylcellulose (vehicle control), AZD1480 (2 µM), the Stat3 inhibitor S3I-201 
(Biovision, 50 µM), epithelial growth factor receptor (EGFR) inhibitor AG1478 (Cell Signaling, 
1µM), or recombinant human IL11 (Genetics Institute, 10 ng/ml) for 10 days.  
 
Immunohistochemistry and Immunofluorescence  
Tissues were fixed and immunohistochemistry performed as described previously (7).  Primary 
antibodies used were rabbit phosphorylated Tyr705 Stat3 (Santa Cruz #9134s, 1:150), rabbit 
Thr202/Tyr204 p42/44 MAPK (Cell Signaling #9101, 1:150), mouse β-catenin (Transduction 
Laboratories, 1:300), mouse BrdU (BD Biosciences, 1:300), rabbit PCNA (Santa Cruz #7907, 
1:100), rabbit c-Myc (Santa Cruz #C1309, 1:200), rabbit Lysozyme (Neomarkers RB-372, 
1:100) and goat p21 (Santa Cruz #Sc-397-G; 1:100). To assess the distribution of PCNA and β-
catenin, we co-stained sections of mouse intestine using primary antibodies detailed above and 
fluorescent secondaries (rabbit IgG Alexa-488 for PCNA and mouse IgG Alexa-546 for β-
catenin).  Slides were tile scanned on a Nikon Ti-E microscope using a 10x PlanApo NA0.3 
objective. The area of tumors was outlined manually to generate binary masks used to measure 
area, average intensity, shape factor, and intensity standard deviation of nuclei with MetaMorph 
v7.7.7. These values were assembled in Microsoft Excel and analysed with FlowJo . 
 
Biochemical analysis 
Gene expression analysis by reverse transcription and quantitative polymerase chain reaction 
(RT-qPCR) was performed using the SybrGreen method (ABI) as described (17). For RT-pPCR 
primer sequences please see Table S1.  Fold change was calculated using the 2-ΔΔCT method (68).  
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Protein lysates were separated by SDS-PAGE and transferred to nitrocellulose. For Western blot 
analysis membranes were blocked in 5 % non-fat milk powder in PBS + 0.05% Tween-20 buffer 
and probed overnight with antibodies detecting p16 (Santa Cruz; #sc-467), Bmi-1 (Millipore; 
#05-637), Actin (Sigma; #A2066) or Gapdh (Santa Cruz; #sc-69778). All primary antibodies 
were diluted 1:1000 in 5% BSA (w/v) or 5% non-fat milk powder(w/v) in PBS + 0.05% Tween-
20 buffer. Membranes were then incubated with an appropriate HRP-conjugated secondary 
antibody diluted at 1:3,000 in PBS + 0.05% Tween-20, for 2 hours at room temperature. Signals 
were visualized with a Chemidoc XRS+ (BioRad, Hercules, CA) chemiluminescence detection 
system. 
 
For ChIP assays, 1 × 107 SW480 or SW480APC cells were stimulated with IL11 (0.5 µg/ml) for 
30 minutes. Chromatin was cross-linked with 1% formaldehyde for 10 minutes and sonicated to 
an average size of 400 base pairs using the Bioruptor Plus (Diagenode, Denville, USA). 
Immunoprecipitation was performed using Protein A Dynabeads (Life Technologies, Mulgrave, 
Australia).  Each sample contained 10 µg of phosphorylated-STAT3 antibody (sc-482X, Santa 
Cruz Biotechnology, CA) or rabbit IgG (#02-6102, Life Technologies, Mulgrave, Australia). The 
crosslinks were reversed in 0.2 M NaCl in the presence of RNaseA (Life Technologies 
Mulgrave, Australia) at 65°C, over night. DNA fragments were purified using phenol chloroform 
extraction and ethanol precipitation. The immunopreciptated DNA was amplified by quantitative 
PCR using primers specific for intron1 of the BMI-1 gene (forward: 5'-GCT GGA GGA CAA 
ATG GAA GA-3'; reverse: 5'-TGG GCT GTC CTA ACG TTT CT-3') and the GAPDH promoter 
(forward: 5'-TAC TAG CGG TTT TAC GGG CG-3'; reverse: 5'- TCG AAC AGG AGG AGC 
AGA GAG CGA-3').  
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Luciferase Reporter Assay 
A 555 bp region around the predicted Stat3 binding site in the first intron of the murine Bmi-1 
gene (40) was amplified from genomic DNA using the forward primer 5'-AAG CTC GAG AGG 
GTT TAA GCA CCT TG-3' and reverse primer 5'-AAG TCT CCC AAA CCT GCA GCA ACT 
AT-3' and subcloned into pGL4_23 [luc2/minP] (Promega) to yield the pBmi-1:luc reporter 
plasmid. HEK293T cells were seeded in DMEM supplemented with 10 % FBS in 96 well plates 
at 1x104 cells/well the day before transfection.  The pBmi-1:luc and pCMV-renilla plasmids were 
co-transfected at a ratio of 40:1 using FuGENE 6 (Roche). Twenty-four hours later, cells were 
stimulated with the indicated concentrations of Hyper IL-6 (gift from S. Rose-John, Kiel, 
Germany) (41) for 4 hours. Luciferase activity was detected using the Dual-Luciferase Reporter 
Assay (Promega) and measured with a Lumistar Galaxy luminometer (Dynatech Laboratories). 
Luciferase assays using TOPFLASH were performed as described (41). Cells were treated with 
vehicle (DMSO), AZD1480 (2µM) or IL11 (10ng/ml) for 30 minutes before cell lysates were 
collected.  
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Supplementary Materials 
 
Fig. S1  gp130-Jak-Stat3 signaling regulates intestinal regeneration and tumorigenesis. 
Fig. S2  gp130-Jak-Stat3 signaling limits induced colonic tumorigenesis in in Lgr5CreERT2; 
Apcfl/fl mice and human CRC xenografts. 
Fig. S3  Gene signature for Wnt and gp130-Jak-Stat3 signaling co-exist in human colorectal 
cancers. 
Fig S4  Xenograft growth is supressed by partial inhibition of the gp130-Jak-Stat3 pathway 
without effecting Stat1. 
Fig. S5  Stimulation of gp130-Jak-Stat3 signaling does not affect aberrant Wnt-β-catenin 
signalling in the SW480 human CRC cell line. 
Fig. S6  Inhibition of gp130-Jak-Stat3 signaling does not affect intestinal homeostasis. 
Fig. S7 Inhibition of gp130-Jak-Stat3 signaling relieves Bmi1-mediated repression of the 
gene encoding p21 intestinal tumors. 
Table S1 Primer sequences used for RT-qPRC 
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FIGURE LEGENDS 
 
Fig. 1.   Impaired gp130-Jak-Stat3 signaling supresses intestinal regeneration in response 
to irradiation and the growth of crypts in organoid culture.  
A Immunohistochemical analysis for the proliferation marker PCNA on sections of small 
intestines collected 72h after γ-irradiation of mice of the indicated genotypes gavaged daily 
with AZD1480 (30 mg/kg) for 3 days prior to and 3 days after irradiation. Scale bar = 100 
µm. The graph shows the quantification of intact, PCNA-positive crypts in cross sections 
from the proximal small intestine. Data are mean ± S.E.M of 3 mice per cohort. * p < 0.04. 
Mann-Whitney U-test. WT = wild-type. 
B Immunohistochemical analysis for c-Myc and β-catenin on sections of small intestines 
from mice of the indicated genotype 72h after γ-irradiation.  Regenerating crypts (black 
arrows) and non-regenerating epithelium (red arrows) are marked.  Scale bar = 50 µm. 
Images are representative of 3 mice per cohort. 
C Graph of the relative mRNA abundance for β-catenin target genes in IECs isolated from 
small intestines of wild-type and gp130ΔStat/+ mice 72 h after γ-irradiation. Data are mean ± 
S.E.M. of 3 mice per cohort. * p < 0.04. Mann-Whitney U-test. 
D Representative organoids grown from crypts of the small intestines of gp130F/F or WT mice 
or from WT mice and cultured in the presence of the Stat3 inhibitor S3I-201 (Stat3i, 7.5 
µM) from day 3 after seeding.  Arrows point to budding crypt-like structures. Scale bar = 
50 µm. The graph shows the quantification of budding crypt-like structures on individual 
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organoids. Crypts per organoid were counted for every organoid in a 10x field of view over 
a 5 day period.  Data are mean ± SD. N=2.  
 
Fig. 2. gp130-Jak-Stat3 signaling is rate-limiting during spontaneous intestinal 
tumorigenesis in ApcMin/+ mice.  
A  Quantification of number and size of tumors in the small intestines and colon of 150 day 
old ApcMin/+ and ApcMin/+; gp130ΔStat/+ mice. Data are mean ± S.E.M. of 8 mice per cohort. * 
p < 0.002. Mann-Whitney U-test. 
B Representative images of emerging colonic tumors labelled with methylene blue in 100 
day old mice of the indicated genotypes.  Scale bar = 500 µm. The graphs show 
quantification of the number and area of intestinal tumors. Data are mean ± S.E.M. of 5 
mice per cohort. *  p < 0.02. Mann-Whitney U-test.  
C Quantification of the number and area of intestinal tumors in mice of the indicated 
genotypes. Data are mean ± S.E.M. of 5 mice per cohort. *  p < 0.02. Mann-Whitney U-
test.  
 
Fig. 3. gp130-Jak-Stat3 signaling is rate-limiting during induced intestinal tumorigenesis in 
Lgr5CreERT2; Apcfl/fl mice. 
A     Representative images of haematoxylin- and eosin-stained cross-sections of small intestines 
from mice of the indicated genotypes and collected 35 days after tamoxifen administration. 
Neoplastic foci (microadenoma) are indicated by arrowheads and tubular adenomas are 
indicated by arrows. Scale bars = 1mm. The graphs show the quantification of the cross-
sectional area of intestinal tumors. Data were normalized for the length of the intestine on 
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the section analysed and represent the mean ± S.E.M. of 3 mice per cohort. * p < 0.04. 
Mann-Whitney U-test.     
B Immunofluorescence staining for β-catenin and PCNA in sections of intestinal tumors from 
adult mice of the indicated genotype 35 days after tamoxifen administration.  Scale bar = 
50 µm.  The graph shows the quantification of β-catenin and PCNA labelled epithelial cells 
in tumors. Data were normalized for the total number of tumor-associated IECs using 
DAPI-stained nuclei as reference and represent the mean ± S.E.M. of 3 mice per cohort. * 
p < 0.04. Mann-Whitney U-test. 
 
Fig. 4. AZD1480 limits intestinal tumorigenesis in in Lgr5CreERT2; Apcfl/fl and ApcMin mice. 
A     Representative images of haematoxylin- and eosin-stained cross-sections of small intestine 
from Lgr5CreERT2; Apcfl/fl mice and collected 35 days after tamoxifen administration and 
daily gavages with AZD1480 (30 mg/kg) or vehicle. Neoplastic foci (microadenoma) are 
indicated by arrowheads and tubular adenomas are indicated by arrows. Scale bars = 1mm. 
The graphs show the quantification of the cross-sectional area of intestinal tumors. Data 
were normalized for the length of the intestine on the section analysed and represent the 
mean ± S.E.M. of 3 mice per cohort. * p < 0.04. Mann-Whitney U-test.     
B Enumeration of total number and size of intestinal tumors in individual ApcMin mice at 6 
weeks of age and 12 weeks of age following treatment with daily gavages of AZD1480 (30 
mg/kg) or vehicle for the last 6 weeks. NSD = not significantly different. Data represent 
the mean ± S.E.M. of 3 mice per cohort. * p < 0.04. Mann-Whitney U-test. 
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Fig. 5. Inhibition of gp130-Jak-Stat3 signaling blocks tumor growth in human CRC cells 
with activating mutations in the Wnt-β-catenin pathway. 
A Graphs of the volume of tumor xenografts in BALB/c-nude mice injected subcutaneously 
with the indicated human CRC cell lines and gavaged daily with AZD1480 (30 mg/kg, 
daily) or vehicle starting on the 5th day after cell injection. Data are mean ± S.E.M. of 8 
tumors per condition. * p < 0.039. Student's t-test. NSD = not significantly different. 
B Representative photograph of SW480 and SW480APC CRC cells grown for 10 days under 
colony forming conditions in soft agar in the presence of AZD1480 (2 µM) or vehicle.  
Scale bar = 200 µm. The graph shows the quantification of normalized number of colonies 
containing >50 cells. Data are mean ± S.E.M. of triplicate cultures from 3 independent 
experiments. * p < 0.04. Mann-Whitney U-test.  
 
Fig. 6. Inhibition of gp130-Jak-Stat3 signaling promotes cell cycle inhibition through Bmi1. 
A Graph of the relative mRNA abundance for the indicated genes in SW480 xenografts from 
mice that were gavaged daily for 35 days with AZD1480 (30mg/kg, daily) or vehicle 
control. Data are mean ± S.E.M. of 3 mice per condition. * p<0.04. Mann-Whitney U-test. 
B Western blot analysis for p16 in intestinal tumors of 18 week old mice of the indicated 
genotypes. Gapdh was used as loading control. Each lane represents an individual mouse. 
C Immunohistochemical analysis of p21 in intestinal tumors of 18 week old mice of the 
indicated genotypes. Scale bar = 100µm. Images are representative of 3 mice per genotype. 
D Immunohistochemical analysis of p21 in SW480 CRC xenografts resected from mice that 
were gavaged daily for 35 days with AZD1480 (30mg/kg, daily) or vehicle control.  Scale 
bar = 100µm. Images are representative of 3 mice. 
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E Graph of the relative enrichment of the indicated loci using ChIP with antibodies targeting 
IgG or phosphorylated Tyr205 Stat3 and lysates from SW480 cells exposed to IL11 
(500ng/ml) or PBS for 30 minutes. Data are mean ± S.E.M. of 3 independent experiments. 
*  p < 0.04. Student’s t-test.       
F Quantification of the number of tumors in the small intestine of 18 week old ApcMin/+ or 
ApcMin/+; Bmi1+/- mice. Data are mean ± S.E.M. of 3 mice per cohort. * p < 0.04. Mann-
Whitney U-test. 
G Schematic representation showing how the gp130-Jak-Stat3-Bmi-1 pathway acts as a 
rheostat to regulate Wnt-β-catenin activated cell proliferation (Apc* = mutated Apc).  
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Fig. S1   gp130-Jak-Stat3 signaling regulates intestinal regeneration and tumorigenesis. 
Fig. S2  gp130-Jak-Stat3 signaling limits induced colonic tumorigenesis in in Lgr5
CreERT2
; Apc
fl/fl 
mice 
and human CRC xenografts. 
Fig. S3   Gene signature for Wnt and gp130-Jak-Stat3 signaling co-exist in human colorectal cancers. 
Fig S4  Xenograft growth is supressed by partial inhibition of the gp130/Jak/Stat3 pathway without 
effecting Stat1. 
Fig. S5  Stimulation of gp130-Jak-Stat3 signaling does not affect aberrant Wnt-β-catenin signalling 
in the SW480 human CRC cell line. 
Fig. S6   Inhibition of gp130-Jak-Stat3 signaling does not affect intestinal homeostasis. 
Fig. S7 Inhibition of gp130-Jak-Stat3 signaling relieves Bmi1-mediated repression of the gene 
encoding p21 intestinal tumors. 
Table S1  Primer sequences used for RT-qPRC 
 
  
 Figure S1. gp130-Jak-Stat3 signaling is required for intestinal regeneration and tumorigenesis.  
(A) Photomicrographs of organoids grown from crypts from the colon or small intestine of wild-type mice exposed 
to vehicle (DMSO), AZD1480 (2µM) or IL-11 (10ng/ml) for 7 days. Scale bar = 100 μm. (B) Quantification of 
organoid size from cultures depicted in (A). Data are mean ± SEM of duplicate cultures from 2 independent 
experiments. * p < 0.04. Mann-Whitney U-test. (C) Photomicrographs of haematoxylin- and eosin-stained sections 
of intestinal tumors of 150 day old Apc
Min/+
 and Apc
Min/+
;gp130
F/F
 , or of Lgr5Cre
ERT2/+
;Apc
fl/fl
;Stat3
fl/+ 
36d after 
tamoxifen are non-invasive and display characteristics of tubular adenomas.  Scale bar = 100 μm. Images are 
representative of 3mice. (D) Relative abundance of the mRNA for the Stat3 target gene Socs3 and for the Wnt-β-
catenin target gene c-Myc in intestinal tumors of 100 day old mice of the indicated genotypes. Data are mean ± SEM 
of 3 mice per cohort. * p < 0.04. Mann Whitney U-test. NSD = not significantly different. (E) Immunohistochemical 
staining for phosphorylated MAPK (Erk1/2) Thr202/Tyr204 MAPK in intestinal tumours of mice of the indicated 
genotypes. Images are representative of 3 mice.  
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Figure S2.  gp130-Jak-Stat3 signaling limits colon tumorigenesis in Lgr5
CreERT2
; Apc
fl/fl 
mice and human CRC 
xenografts. (A) Haematoxylin- and eosin-stained cross-sections of colons from mice of the indicated genotypes 
collected 35 days after tamoxifen administration. Some mice also received 35 days of daily gavage of AZD1480 
(30mg/kg, daily) or vehicle. Neoplastic foci (arrowhead) and tubular adenomas (arrows) are indicated. Scale bar = 
1mm. 
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Fig. S3. Gene signature for Wnt and gp130-Jak-Stat3 signaling co-exist in human colorectal cancers.  
Heatmaps of the Z-scores representing the relative abundance of mRNAs of β-catenin and Stat3 target genes in CRC 
and normal colon biopsies.  Oncomine (http://oncomine.org) was used to extract data from 12 normal and 70 CRC 
samples from Hong et al. [GSE9348; (27)] and from 24 normal and 36 CRC samples from Skrzypczak et al. 
[GSE20916; (28) ]. Z-scores were calculated by subtracting the mean for the corresponding gene probe and dividing 
by the standard deviation. Individual samples are aligned vertically and ordered according to the average Z-score 
across samples. Fold change (FC) was calculated as the mean of CRC samples divided by the mean of control 
samples for each gene. p < 0.001 comparing normal to CRC samples for each gene. Mann-Whitney U test.  
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 Fig S4. Xenograft growth is supressed by partial inhibition of the gp130-Jak-Stat3 pathway without effecting 
Stat1. (A) Tumor xenografts resected from BALB/c-nude mice injected subcutaneously with human SW480 or 
LIM1899 CRC cell lines and gavaged daily with AZD1480 (30 mg/kg) or vehicle starting on the 5
th
 day after cell 
injection. Photograph of representative tumors were taken 40 (SW480 cells) or 30 (LIM1899 cells) days after cell 
injection. Scale bar = 1 cm (B) Immunohistochemical analysis for Stat1 in intestinal tumours from mice of the 
indicated genotype 36 days after tamoxifen administration. Images are representative of 3 mice. (C) Quantification 
of the relative mRNA abundance for the interferon-γ-Stat1 target gene IP-10 in xenografts resected from AZD1480 
and vehicle-treated mice from Fig. 5A (n = 3 mice).   
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 Figure S5. Stimulation of gp130-Jak-Stat3 signaling does not affect aberrant Wnt-β-catenin signalling in the 
SW480 human CRC cell line. (A) Immunofluorescence staining for β-catenin or phosphorylated Tyr205 Stat3 (P-
Stat3) in SW480 and SW480
APC
 cells after exposure to vehicle (DMSO) or AZD1480 (2μM). Scale bar = 20 μm. (B) 
TOPFLASH-reporter activity in SW480 and SW480
APC
 cells.  Luciferase activity was normalized to Renilla 
luciferase. Data are mean ± SEM of triplicates from 3 independent experiments. *p = 0.04; Mann-Whitney U-test. 
(C and D) Western blot analysis for phosphorylated Tyr
205
 Stat3 (P- Stat3), total Stat3 (Stat3) and β-catenin in 
SW480 or SW480
APC
 cells after 30 min exposure to the indicated amount of IL11 and AZD1480. Actin was used as 
a loading control. (E) TOPFLASH-reporter activity in SW480 and SW480
APC
 cells exposed to AZD1480 (2μM) or 
IL11 (50ng/ml) for 30 min. Data are mean ± SEM of triplicates from 3 independent experiments. NSD = not 
significantly different. Mann-Whitney U-test. (F) Quantification of the relative mRNA abundance of the Stat3 target 
gene Socs3 in SW480 and SW480
APC
 cells grown for 10 days under colony forming conditions in soft agar in the 
presence of AZD1480 (2μM), Stat3 inhibitor S3I-201 (50μM), IL11 (10ng/ml), EGFR inhibitor AG1478 (1μM), or 
vehicle (DMSO). Data are normalized to the vehicle-treated SW480 cells arbitrarily set as 1 and represent the mean 
± SEM of triplicates from 3 independent experiments. * p < 0.04. Mann-Whitney U-test.  
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Figure S6. Inhibition of gp130-Jak-Stat3 signaling does not affect intestinal homeostasis.  
(A) Immunohistochemical analysis of cell proliferation (BrdU), goblet cells (periodic acid-Schiff, PAS), and Paneth 
cells (lysozyme) in the small intestines of BALB/c-nude mice gavaged daily with AZD1480 (30mg/kg) or vehicle 
from day 5 to 21 after SW480 cell xenograft injection. Scale bar = 50 μm. Images are representative of 6 mice. (B) 
Quantification of the relative mRNA abundance for Wnt/β-catenin target genes, and Socs3, in IECs isolated from 
BALB/c-nude mice shown in Fig. 5A, or (C) body weight of the same mice. Data are mean ± SEM of at least 5 mice 
per cohort. * p < 0.04. Mann-Whitney U-test.  
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Figure S7. Inhibition of gp130-Jak-Stat3 signaling relieves Bmi1-mediated repression of the gene encoding 
p21 intestinal tumors. (A) Immunohistochemical analysis for p21 on intestinal tumors from with the indicated 
genotypes 36 days after tamoxifen administration. Images are representative of 6 mice. (B) Immunohistochemical 
analysis of sections of SW480 tumor xenografts from Balb/C nude mice gavaged daily for 40 days with AZD1480 
or vehicle from Fig. 5A. Images are representative of 6 mice. (C) Western blot analysis for Bmi-1 in lysates of IECs 
isolated from wild-type (WT) and gp130
F/F 
mice.  β-actin was used as a loading control. Each lane represents an 
individual mouse. (D) Quantification of the relative mRNA abundance for Socs3 and Bmi-1 in IECs isolated from 
gp130
F/F 
mice 30 minutes after a single intraperitoneal injection of recombinant IL11 (5µg). Fold changes was 
calculated by comparing mRNA from IEC isolated from unijected mice. Data are mean ± SEM of 3 mice per 
condition. * p < 0.04. Mann-Whitney U-test. (E) Schematic outline of the position of the putative Stat3 binding site 
(red line) in intron 1 of the murine Bmi-1 gene. A 555 base pair fragment encompassing this sequence was amplified 
to construct the pBmi1:luc Luciferase reporter. The open box denotes non-coding exon 1, black boxes indicate 
coding exons 2 and 3. (F) Relative luciferase activity in HEK293T cells transfected with pBmi1:luc and pCMV-
Renilla after 24h exposure to the indicated concentrations of Hyper IL6.  pBmi1:luc activation was normalized to 
Renilla luciferase activity. Data are mean ± S.E.M. of triplicates from 3 independent experiments. * p<0.05. 
Student’s t-test. 
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CD44/for: 5’ - GTC TGC ATC GCG GTC AAT AG - 3’ 
CD44/rev: 5’ - GGT CTC TGA TGG TTC CTT GTT C - 3’ 
Cmyc/for: 5’ - TAG TGC TGC ATG AGG AGA CA - 3’ 
Cmyc/rev: 5’ - GGT TTG CCT CTT CTC CAC AG - 3’ 
CyclinD1/for: 5’ - GCA CAA CGC ACT TTC TTT CCA - 3’ 
CyclinD1/rev: 5’ - CGC AGG CTT GAC TCC AGA AG - 3’ 
Gapdh/for: 5' - CAA CTC ACT CAA GAT TGT CAG CAA - 3' 
Gapdh/rev: 5' - TAC TTG GCA GGT TTC TCC AGG C - 3' 
Socs3/for: 5' - GCG GGC ACC TTT CTT ATC C - 3' 
Socs3/rev: 5' - TCC CCG ACT GGG TCT TGA C - 3' 
Bmi1/forw: 5' - CAA AAC CAG ACC ACT CCT GAA - 3' 
Bmi1/rev: 5' - TCT TCT TCT CTT CAT CTC ATT TTT GA - 3'  
Axin2/forw: 5'- CCA TGA CGG ACA GTA GCG TA - 3'  
Axin2/rev: 5' - GCC ATT GGC CTT CAC ACT - 3' 
CyclinD2/forw: 5' - CAC CGA CAA CTC TGT GAA GC - 3' 
CyclinD2/rev: 5' - TCC ACT TCA GCT TAC CCA ACA - 3'  
Fzd7/forw: 5' - CGT CTT CAG CGT GCT CTA CA - 3'  
Fzd7/rev: 5' - TCA TAA AAG TAG CAG GCC AAC A - 3' 
Lgr5/forw: 5' - CTT CAC TCG GTG CAG TGC T - 3' 
Lgr5/rev: 5' - GAT CAG CCA GCT ACC AAA TAG G - 3' 
SOCS3/forw: 5' - GAC TTC GAT TCG GGA CCA G - 3'  
SOCS3/rev: 5' - AAC TTG CTG TGG GTG ACC AT - 3'  
CDKN1A/forw: 5' - TGC GTT CAC AGG TGT TTC TG - 3' 
CDKN1A/rev: 5' - AGC TGC TCG CTG TCC ACT - 3' 
BMI1/forw: 5' - CCA TTG AAT TCT TTG ACC AGA A - 3' 
BMI1/rev: 5' - CTG CTG GGC ATC GTA AGT ATC - 3' 
CCND1/forw: 5' - GCC GAG AAG CTG TGC ATC - 3' 
CCDN1/rev: 5' - CCA CTT GAG CTT GTT CAC CA - 3' 
CMYC/forw: 5' - GCT GCT TAG ACG CTG GAT TT - 3' 
CMYC/rev: 5' - TAA CGT TGA GGG GCA TCG - 3' 
LGR5/forw: 5' - ACC AGA CTA TGC CTT TGG AAA C - 3' 
LGR5/rev: 5' - TTC CCA GGG AGT GGA TTC TAT - 3' 
CXCL10/forw: 5' - GAA AGC AGT TAG CAA GGA AAG GT - 3' 
CXCL10/rev: 5' - GAC ATA TAC TCC ATG TAG GGA AGT GA - 3' 
GAPDH/forw: 5' - CCC CGG TTT CTA TAA ATT GAG C - 3' 
GAPDH/rev: 5' - CAC CTT CCC CAT GGT GTC T - 3' 
 
Table S1. Primer sequences used for RT-qPRC. 
  
 
 
